{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:48:23Z","timestamp":1788378503066,"version":"build-2803163510"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bioorg.2023.106934","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T14:55:37Z","timestamp":1698072937000},"page":"106934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities"],"prefix":"10.1016","volume":"142","author":[{"given":"Xia-Wen","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Long","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Dong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RenRen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106934_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2023.106934_b0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","article-title":"Cellular functions regulated by Src family kinases","volume":"13","author":"Thomas","year":"1997","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"2\u20133","key":"10.1016\/j.bioorg.2023.106934_b0015","first-page":"121","article-title":"Regulation, substrates and functions of src","volume":"1287","author":"Brown","year":"1996","journal-title":"BBA"},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/35073094","article-title":"The hunting of the Src","volume":"2","author":"Martin","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106934_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020135","article-title":"Regulation of Fibroblast Cell Polarity by Src Tyrosine Kinase","volume":"9","author":"Katoh","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0030","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3816\/CLC.2010.n.030","article-title":"Src inhibitors in lung cancer: current status and future directions","volume":"11","author":"Rothschild","year":"2010","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.03.012","article-title":"Src kinase regulation by phosphorylation and dephosphorylation","volume":"331","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0045","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/emboj\/19.5.964","article-title":"A phosphotyrosine displacement mechanism for activation of Src by PTPalpha","volume":"19","author":"Zheng","year":"2000","journal-title":"EMBO J."},{"issue":"20","key":"10.1016\/j.bioorg.2023.106934_b0050","doi-asserted-by":"crossref","first-page":"20752","DOI":"10.1074\/jbc.M309865200","article-title":"A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity","volume":"279","author":"Chong","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrm779","article-title":"v-Src's hold over actin and cell adhesions","volume":"3","author":"Frame","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0065","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ctrv.2010.08.003","article-title":"Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention","volume":"37","author":"Wadhawan","year":"2011","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106934_b0070","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4065\/81.9.1241","article-title":"Biology of platelet-derived growth factor and its involvement in disease","volume":"81","author":"Alvarez","year":"2006","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0075","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/1078-0432.CCR-05-2692","article-title":"Treatment for advanced tumors: SRC reclaims center stage","volume":"12","author":"Summy","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"49","key":"10.1016\/j.bioorg.2023.106934_b0080","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/ijo.2011.897","article-title":"Differential roles of Src in transforming growth factor-ss regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells","volume":"38","author":"Ungefroren","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2023.106934_b0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2023.106934_b0095","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2174\/1570159X18666200814180218","article-title":"Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain","volume":"19","author":"Nie","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105508","article-title":"Tyrosine Kinase Src Is a Regulatory Factor of Bone Homeostasis","volume":"23","author":"Matsubara","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/biom12070984","article-title":"Src Family Kinases: A Potential Therapeutic Target for Acute Kidney Injury","volume":"12","author":"Li","year":"2022","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0115","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s12276-022-00810-3","article-title":"Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress","volume":"54","author":"Dorotea","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"45","key":"10.1016\/j.bioorg.2023.106934_b0120","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","article-title":"Src: coordinating metabolism in cancer","volume":"41","author":"Pelaz","year":"2022","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.bioorg.2023.106934_b0125","first-page":"3510","article-title":"Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy","volume":"286","author":"Parkin","year":"2019","journal-title":"F. E. B. S. J."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/s43042-021-00172-x","article-title":"Recent advances in pharmacological diversification of Src family kinase inhibitors","volume":"22","author":"Negi","year":"2021","journal-title":"Egyptian Journal of Medical Human Genetics"},{"issue":"12","key":"10.1016\/j.bioorg.2023.106934_b0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.11569\/wcjd.v29.i12.621","article-title":"Recent progress in SRC targeted therapy for pancreatic cancer","volume":"29","author":"Li","year":"2021","journal-title":"World Chinese Journal of Digestology"},{"key":"10.1016\/j.bioorg.2023.106934_b0140","doi-asserted-by":"crossref","unstructured":"S. Martellucci, L. Clementi, S. Sabetta, V. Mattei, L. Botta, A. Angelucci, Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far, Cancers (Basel) 12(6) (2020).","DOI":"10.3390\/cancers12061448"},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2174\/1871520616666160223111800","article-title":"Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors","volume":"16","author":"Olgen","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106934_b0150","unstructured":"A.A.M.E.-D. Ahmed A. El-Rashedy, Drug design of Src Kinase inhibitor: An overview., J. I. P. B. S. 5(1) (2018) 51-59."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cmdc.200800320","article-title":"C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src\/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines","volume":"4","author":"Santucci","year":"2009","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.bioorg.2023.106934_b0160","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/acs.jmedchem.5b00270","article-title":"Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer","volume":"58","author":"Zhang","year":"2015","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2023.106934_b0165","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmcl.2011.07.079","article-title":"Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells","volume":"21","author":"Radi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0170","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/ml4000782","article-title":"Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src\/Abl Inhibitors","volume":"4","author":"Vignaroli","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0175","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1021\/jm1012819","article-title":"Design, Synthesis, Biological Activity, and ADME Properties of Pyrazolo[3,4-d]pyrimidines Active in Hypoxic Human Leukemia Cells: A Lead Optimization Study","volume":"54","author":"Radi","year":"2011","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm5013159","article-title":"Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma","volume":"58","author":"Tintori","year":"2015","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0185","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acsmedchemlett.9b00530","article-title":"Development of Pyrazolo[3,4-d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme","volume":"11","author":"Greco","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2023.106934_b0190","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1016\/j.bmcl.2018.09.024","article-title":"Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment","volume":"28","author":"Molinari","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106934_b0195","doi-asserted-by":"crossref","unstructured":"A.L. Fallacara, C. Zamperini, A. Podolski-Renic, J. Dinic, T. Stankovic, M. Stepanovic, A. Mancini, E. Rango, G. Iovenitti, A. Molinari, F. Bugli, M. Sanguinetti, R. Torelli, M. Martini, L. Maccari, M. Valoti, E. Dreassi, M. Botta, M. Pesic, S. Schenone, A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src\/P-Glycoprotein Inhibitor, Cancers (Basel) 11(6) (2019).","DOI":"10.3390\/cancers11060848"},{"key":"10.1016\/j.bioorg.2023.106934_b0200","doi-asserted-by":"crossref","unstructured":"M. Nesovic, A. Divac Rankov, A. Podolski-Renic, I. Nikolic, G. Tasic, A. Mancini, S. Schenone, M. Pesic, J. Dinic, Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo, Cancers (Basel) 12(6) (2020).","DOI":"10.3390\/cancers12061570"},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11070884","article-title":"Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells","volume":"11","author":"Kostic","year":"2021","journal-title":"Brain Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071399","article-title":"Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells","volume":"14","author":"Monteleone","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0215","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1021\/acsmedchemlett.9b00538","article-title":"AuNP Pyrazolo[3,4-d]pyrimidine Nanosystem in Combination with Radiotherapy against Glioblastoma","volume":"11","author":"Molinari","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030659","article-title":"The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma","volume":"10","author":"Rango","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4155\/fmc.10.272","article-title":"Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases","volume":"3","author":"Cox","year":"2011","journal-title":"Future Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106934_b0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/10409238.2013.875513","article-title":"Bivalent inhibitors of protein kinases","volume":"49","author":"Gower","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cmdc.200900252","article-title":"Bisubstrate inhibitors of protein kinases: from principle to practical applications","volume":"5","author":"Lavogina","year":"2010","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/83028","article-title":"Mechanism-based design of a protein kinase inhibitor","volume":"8","author":"Parang","year":"2001","journal-title":"Nat. Struct. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0245","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cb501048b","article-title":"Exquisitely Specific Bisubstrate Inhibitors of c-Src Kinase","volume":"10","author":"Brandvold","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106934_b0250","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1074\/jbc.271.2.695","article-title":"Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation","volume":"271","author":"Hanke","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0255","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1074\/jbc.M209321200","article-title":"The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases","volume":"278","author":"Tatton","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0260","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/jm201265f","article-title":"Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen","volume":"55","author":"Jester","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0265","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1021\/jm3003944","article-title":"Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors","volume":"55","author":"Diner","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0270","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1021\/acs.jmedchem.6b00065","article-title":"Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase","volume":"59","author":"Fraser","year":"2016","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2023.106934_b0275","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-21-0613","article-title":"A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability","volume":"81","author":"Temps","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2023.106934_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108108","article-title":"The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease","volume":"197","author":"Sergeys","year":"2020","journal-title":"Exp. Eye Res."},{"issue":"18","key":"10.1016\/j.bioorg.2023.106934_b0285","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1158\/0008-5472.CAN-10-0391","article-title":"Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0290","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.7150\/thno.15083","article-title":"Gas6\/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt\/GSK-3beta\/beta-catenin Signaling","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"issue":"20","key":"10.1016\/j.bioorg.2023.106934_b0295","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/jnci\/djt263","article-title":"Combating resistance to anti-IGFR antibody by targeting the integrin beta3-Src pathway","volume":"105","author":"Shin","year":"2013","journal-title":"J. Natl Cancer Inst."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0300","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/JTO.0b013e31818180f5","article-title":"The insulin-like growth factor pathway in lung cancer","volume":"3","author":"Dziadziuszko","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0305","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.7150\/thno.48865","article-title":"Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor\/Src\/AXL-targeting small molecule kinase inhibitor","volume":"11","author":"Lee","year":"2021","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0310","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/annonc\/mdq757","article-title":"Src: a potential target for the treatment of triple-negative breast cancer","volume":"22","author":"Tryfonopoulos","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0315","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro","volume":"105","author":"Finn","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"21","key":"10.1016\/j.bioorg.2023.106934_b0320","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1158\/1078-0432.CCR-11-0288","article-title":"Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study","volume":"17","author":"Finn","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0325","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/1078-0432.CCR-13-0583","article-title":"New strategies for triple-negative breast cancer\u2013deciphering the heterogeneity","volume":"20","author":"Mayer","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106934_b0330","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.tips.2015.08.009","article-title":"Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease","volume":"36","author":"Kalimutho","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"25","key":"10.1016\/j.bioorg.2023.106934_b0335","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/onc.2012.320","article-title":"Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways","volume":"32","author":"Bianchi-Smiraglia","year":"2013","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.bioorg.2023.106934_b0340","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1021\/acs.jmedchem.6b00943","article-title":"From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer","volume":"59","author":"Zhang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0345","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/cas.13929","article-title":"Preclinical pharmacodynamic evaluation of a new Src\/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma","volume":"110","author":"Yang","year":"2019","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0350","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bmc.2011.10.085","article-title":"Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity","volume":"20","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2023.106934_b0355","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1016\/j.bmc.2011.06.044","article-title":"The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase","volume":"19","author":"Li","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2023.106934_b0360","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1016\/j.bmcl.2005.08.106","article-title":"New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors","volume":"15","author":"Barlaam","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"22","key":"10.1016\/j.bioorg.2023.106934_b0365","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src\/Abl Kinase Inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0370","first-page":"1668","article-title":"Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility","volume":"10","author":"Weng","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"48","key":"10.1016\/j.bioorg.2023.106934_b0375","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1039\/c3ob41161c","article-title":"Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors","volume":"11","author":"Li","year":"2013","journal-title":"Org. Biomol. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106934_b0380","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/cmdc.201500428","article-title":"Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors","volume":"10","author":"Francini","year":"2015","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.bioorg.2023.106934_b0385","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23092369","article-title":"Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors","volume":"23","author":"Francini","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106934_b0390","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1517\/17460440802580106","article-title":"Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition","volume":"3","author":"Backes","year":"2008","journal-title":"Exp. Opin. Drug Discov."},{"issue":"27","key":"10.1016\/j.bioorg.2023.106934_b0395","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106934_b0400","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0405","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106934_b0410","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.chembiol.2006.05.015","article-title":"A general strategy for creating \u201cinactive-conformation\u201d abl inhibitors","volume":"13","author":"Okram","year":"2006","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0415","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"21","key":"10.1016\/j.bioorg.2023.106934_b0420","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215343","article-title":"UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.bioorg.2023.106934_b0425","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1158\/1078-0432.CCR-15-2158","article-title":"UM-164: A Potent c-Src\/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer","volume":"22","author":"Gilani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0430","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1080\/14756366.2022.2117317","article-title":"Synthesis and biological activity evaluation of 3-(hetero) arylideneindolin-2-ones as potential c-Src inhibitors","volume":"37","author":"Princiotto","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106934_b0435","unstructured":"H. Zhang, H. Hao, K. Zhu, Compound targeting c-src kinase sh3 domain and application thereof. CN 115677617A."},{"key":"10.1016\/j.bioorg.2023.106934_b0440","unstructured":"H.G. Choi, J.B. Son, S. Kim, S. Lee, E. Ko, J. Cho, S.Y. Kang, S.Y. Kim, J.-H. Park, Y.K. Ko, H.Y. Ryu, N.D. Kim, H. Kim, Y. Lee, S.-H. Lee, D. Kim, S.J. Lee, S. Hong, S.H. Min, S. Lee, D.K. Choi, J.H. Bae, E. Hong, T.-H. Jang, J. Song, S. Kim, S.K. Yoon, Preparation of novel imidazopyridine derivatives, and pharmaceutical compositions containing them as active ingredients for preventing or treating cancer. WO 2017222285."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0445","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4062\/biomolther.2020.088","article-title":"KF-1607, a Novel Pan Src Kinase Inhibitor, Attenuates Obstruction-Induced Tubulointerstitial Fibrosis in Mice","volume":"29","author":"Dorotea","year":"2021","journal-title":"Biomol. Ther (seoul)"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0450","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/acsmedchemlett.7b00545","article-title":"Synthesis and Biological Screening of Pyrano[3,2-c]quinoline Analogues as Anti-inflammatory and Anticancer Agents","volume":"9","author":"Upadhyay","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106934_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105344","article-title":"Development of 2\u2032-aminospiro [pyrano[3,2\u2013c]quinoline]-3\u2032-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation","volume":"116","author":"Ramadan","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0460","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bmc.2016.11.035","article-title":"Structure-guided development of covalent TAK1 inhibitors","volume":"25","author":"Tan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0465","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bmc.2016.11.034","article-title":"Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors","volume":"25","author":"Tan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0470","first-page":"818","article-title":"Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome, Cell","volume":"26","author":"Rao","year":"2019","journal-title":"Chem. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0475","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1021\/acs.jmedchem.9b01502","article-title":"Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine","volume":"63","author":"Du","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106934_b0480","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","article-title":"Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)","volume":"61","author":"Smolinski","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0485","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106934_b0490","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/acs.jmedchem.0c01961","article-title":"Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106934_b0495","article-title":"Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src\/STAT3 Signaling","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0500","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/cb5008376","article-title":"Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges","volume":"10","author":"Breen","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0505","first-page":"2576","article-title":"Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways","volume":"12","author":"Yihua Lai","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0510","first-page":"2576","article-title":"Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways","volume":"12","author":"Lai","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2023.106934_b0515","unstructured":"B. Liu, J. Zhang, X. Jiang, B. Deng, Tyrosine kinase Src inhibitor dihydrotanshinone I and application as antitumor agent, CN 110759881."},{"key":"10.1016\/j.bioorg.2023.106934_b0520","unstructured":"B. Liu, Y. Zhou, Y. Wu, K. Lin, Application of gambogic acid in preparing tyrosine kinase Src inhibitor or drug for treating liver cancer, CN 113952329."},{"key":"10.1016\/j.bioorg.2023.106934_b0525","unstructured":"J. Zhang, B. Liu, N. Liu, B. Deng, X. Jiang, Application of dauricine as Src inhibitor in preparing drug for treating melanoma, CN 109893527."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0530","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nature Chem. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0535","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: New Approaches to Protein Degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106934_b0540","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0545","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acsmedchemlett.5b00167","article-title":"Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration","volume":"6","author":"Kwarcinski","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106934_b0550","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1021\/cb300337u","article-title":"Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine","volume":"7","author":"Kwarcinski","year":"2012","journal-title":"ACS Chem. Biol."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2023.106934_b0555","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2013.04.016","article-title":"RBx10080307, a dual EGFR\/IGF-1R inhibitor for anticancer therapy","volume":"711","author":"Tandon","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"6241","key":"10.1016\/j.bioorg.2023.106934_b0560","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0565","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nature Chem. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0570","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081948","article-title":"Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src","volume":"25","author":"Manda","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0575","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/cancers6031736","article-title":"The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models","volume":"6","author":"Bladt","year":"2014","journal-title":"Cancers (basel)"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106934_b0580","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040548","article-title":"Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells","volume":"11","author":"Gaule","year":"2019","journal-title":"Cancers (basel)"},{"issue":"6824","key":"10.1016\/j.bioorg.2023.106934_b0585","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0590","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0258-1","article-title":"Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent","volume":"9","author":"Leonard","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0595","article-title":"Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo, Plos","volume":"18","author":"Wei","year":"2023","journal-title":"One"},{"key":"10.1016\/j.bioorg.2023.106934_b0600","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.910505","article-title":"Concurrent inhibition of FAK\/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors","volume":"12","author":"Gu","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0605","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-08-3127","article-title":"Combined Src and Aromatase Inhibition Impairs Human Breast Cancer GrowthIn vivoand Bypass Pathways Are Activated in AZD0530-Resistant Tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0610","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-010-1024-7","article-title":"Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo","volume":"128","author":"Chen","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"19","key":"10.1016\/j.bioorg.2023.106934_b0615","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-17-3697","article-title":"Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells","volume":"24","author":"Simpkins","year":"2018","journal-title":"Clini. Cancer Res."},{"key":"10.1016\/j.bioorg.2023.106934_b0620","doi-asserted-by":"crossref","unstructured":"J.C. Dawson, A. Munro, K. Macleod, M. Muir, P. Timpson, R.J. Williams, M. Frame, V.G. Brunton, N.O. Carragher, Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment, Mol. Oncol. (2021).","DOI":"10.1101\/2021.08.27.457893"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0625","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1172\/JCI70259","article-title":"Combined SFK\/MEK inhibition prevents metastatic outgrowth of dormant tumor cells","volume":"124","author":"El Touny","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"30","key":"10.1016\/j.bioorg.2023.106934_b0630","doi-asserted-by":"crossref","first-page":"29991","DOI":"10.18632\/oncotarget.5031","article-title":"Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma","volume":"6","author":"Chua","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0635","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/onc.2012.25","article-title":"Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion","volume":"32","author":"Ferguson","year":"2012","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.bioorg.2023.106934_b0640","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4155\/fmc-2018-0416","article-title":"Thiazole in the targeted anticancer drug discovery","volume":"11","author":"Ayati","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106934_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111786","article-title":"6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies","volume":"185","author":"Toolabi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2023.106934_b0650","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/1078-0432.CCR-13-1559","article-title":"Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer","volume":"20","author":"Yoshida","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106934_b0655","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41416-019-0428-3","article-title":"Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance","volume":"120","author":"Creelan","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106934_b0660","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/187152007781668715","article-title":"PARP inhibitor development for systemic cancer targeting","volume":"7","author":"Zaremba","year":"2007","journal-title":"Anticancer Agents Med Chem."},{"issue":"6082","key":"10.1016\/j.bioorg.2023.106934_b0665","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.1216338","article-title":"Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1","volume":"336","author":"Langelier","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106934_b0670","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2023.106934_b0675","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-20-2483","article-title":"Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"50","key":"10.1016\/j.bioorg.2023.106934_b0680","doi-asserted-by":"crossref","first-page":"22494","DOI":"10.1002\/anie.202006725","article-title":"Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)","volume":"59","author":"Sinatra","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"40","key":"10.1016\/j.bioorg.2023.106934_b0685","doi-asserted-by":"crossref","first-page":"17525","DOI":"10.1002\/anie.202001205","article-title":"Identification of Histone deacetylase (HDAC)-Associated Proteins with DNA-Programmed Affinity Labeling","volume":"59","author":"Zhang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106934_b0690","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acs.jmedchem.0c01763","article-title":"Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2023.106934_b0695","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2020002297","article-title":"Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy","volume":"4","author":"Islam","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2023.106934_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114224","article-title":"Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective","volume":"182","author":"Gao","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106934_b0705","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/ijc.33047","article-title":"Cotargeting BET proteins overcomes resistance arising from PI3K\/mTOR blockade-induced protumorigenic senescence in colorectal cancer","volume":"147","author":"Lee","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106934_b0710","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdermsci.2021.01.004","article-title":"Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"101","author":"Jimura","year":"2021","journal-title":"J. Dermatol. Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106934_b0715","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.18632\/oncotarget.1992","article-title":"Blocking the formation of radiation-induced breast cancer stem cells","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bioorg.2023.106934_b0720","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1248\/bpb.b21-00353","article-title":"Disulfiram Synergizes with SRC Inhibitors to Suppress the Growth of Pancreatic Ductal Adenocarcinoma Cells in Vitro and in Vivo","volume":"44","author":"Li","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2023.106934_b0725","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton therapy - Present and future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"10.1016\/j.bioorg.2023.106934_b0730","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194745","article-title":"Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line","volume":"20","author":"Cammarata","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106934_b0735","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113917","article-title":"SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines","volume":"21","author":"Torrisi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106934_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108876","article-title":"Paradoxical activation of c-Src as a drug-resistant mechanism","volume":"34","author":"Higuchi","year":"2021","journal-title":"Cell Rep."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823005953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823005953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:47:10Z","timestamp":1758617230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823005953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":148,"alternative-id":["S0045206823005953"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106934","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106934"}}